Ligand Pharmaceuticals Inc

LGND

190.440USD

-1.250-0.65%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Ligand Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

24 / 159

Overall Ranking

71 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ligand Pharmaceuticals Inc Highlights

StrengthsRisks

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 79.51, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 20.54M shares, decreasing 1.52% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 108.93K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.11.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

243.444

Target Price

+27.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Ligand Pharmaceuticals Inc is 8.43, ranking 69 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 115.46M, representing a year-over-year increase of 122.85%, while its net profit experienced a year-over-year increase of 1735.15%.

Score

Industry at a Glance

Previous score

8.43

Change

0



Financials

7.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.68

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Ligand Pharmaceuticals Inc is 7.25, ranking 86 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 79.51, which is 9.90% below the recent high of 87.38 and 797.34% above the recent low of -554.46.

Score

Industry at a Glance

Previous score

7.25

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Ligand Pharmaceuticals Inc is 8.75, ranking 10 out of 159 in the Pharmaceuticals industry. The average price target is 232.50, with a high of 275.00 and a low of 220.00.

Score

Industry at a Glance

Previous score

8.75

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Ligand Pharmaceuticals Inc is 7.40, ranking 59 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 208.51 and the support level at 174.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.48

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ligand Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.36%, representing a quarter-over-quarter increase of 1.91%. The largest institutional shareholder is The Vanguard, holding a total of 2.07M shares, representing 10.51% of shares outstanding, with 1.12% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.63M

-1.05%

The Vanguard Group, Inc.

Star Investors

2.07M

-0.63%

Janus Henderson Investors

1.04M

-1.73%

Nomura Investment Management Business Trust

751.79K

-18.86%

State Street Investment Management (US)

749.36K

-0.05%

Chicago Capital, LLC

568.61K

-0.56%

Dimensional Fund Advisors, L.P.

523.91K

-25.64%

MFS Investment Management

541.85K

+59.49%

Stephens Investment Management Group, LLC

554.54K

-8.31%

Congress Asset Management Company, LLP

667.31K

+2.99%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ligand Pharmaceuticals Inc is 7.80, ranking 34 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Ligand Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Ligand Pharmaceuticals Inc

LGND

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment